Bio Path Holdings Top Insiders

BPTHDelisted Stock  USD 0.19  0.01  5.00%   
Bio Path employs about 10 people. The company is managed by 11 executives with a total tenure of roughly 11 years, averaging almost 1.0 years of service per executive, having 0.91 employees per reported executive. Assessment of Bio Path's management performance can provide insight into the firm performance.
Alan MacKenzie  Insider
Consultant
Thomas Walker  Insider
Consultant
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Bio Path Management Team Effectiveness

The company has return on total asset (ROA) of (1.9409) % which means that it has lost $1.9409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.5974) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities.

Bio Path Workforce Comparison

Bio Path Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 823. Bio Path claims roughly 10.0 in number of employees contributing just under 2% to equities under Health Care industry.

Bio Path Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Path insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Path's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bio Path insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Bio Path Notable Stakeholders

A Bio Path stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bio Path often face trade-offs trying to please all of them. Bio Path's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bio Path's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Douglas MorrisCo-Founder and DirectorProfile
Michael MBAVP OperationsProfile
Alan MacKenzieConsultantProfile
Thomas WalkerConsultantProfile
MBA AshizawaDevelopment ResearchProfile
Peter MBAChairman, CoFounderProfile
Jeffery MDConsultantProfile
Victoria RacRegulatory ConsultantProfile
Anthony PriceAccounting FinanceProfile
MBA MBADevelopment ResearchProfile
Anthony MBAAccounting FinanceProfile

About Bio Path Management Performance

The success or failure of an entity such as Bio Path Holdings often depends on how effective the management is. Bio Path management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.
The data published in Bio Path's official financial statements typically reflect Bio Path's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Bio Path's quantitative information. For example, before you start analyzing numbers published by Bio accountants, it's essential to understand Bio Path's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.

Bio Path Workforce Analysis

Traditionally, organizations such as Bio Path use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bio Path within its industry.

Bio Path Manpower Efficiency

Return on Bio Path Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.6M
Net Loss Per Executive1.5M
Working Capital Per Employee113.6K
Working Capital Per Executive103.3K
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Consideration for investing in Bio OTC Stock

If you are still planning to invest in Bio Path Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bio Path's history and understand the potential risks before investing.
Commodity Directory
Find actively traded commodities issued by global exchanges
Equity Valuation
Check real value of public entities based on technical and fundamental data
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk